References
- 1. Singh R, Rao HK, Singh TG. Advanced glycated end products (ages) in diabetes and its complications: an insight. Plant Arch. 2020; 20(1): 3838-3841.
- 2. Sharma VK, Singh TG. Chronic Stress and Diabetes Mellitus: Interwoven Pathologies. Curr Diabetes Rev. 2019;16(6): 546-556.
- 3. Olokoba AB, Obateru OA, Olokoba LB. Type 2 Diabetes Mellitus: A Review of Current Trends. Oman Med J. 2012; 27(4): 269–273.
- 4. Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus – present and future perspective. Nat. Rev. Endocrinol. 2011; 8(4):228-36.
- 5. Singh R, Rao HK, Singh TG. Neuropathic pain in Diabetes Mellitus: Challenges and Future Trends. Obes Med. 2020; 18.100215.
- 6. Jothivel N, Ponnusamy SP, Appachi M. Antidiabetic activities of methanol leaf extract of Costus pictus D. Don in alloxan-induced diabetic rats. J health sci. 2007; 53(6):655-663.
- 7. Drucker D, Easley C, Kirkpatrick P. News and analysis. Nat Rev Drug Discov. 2007; 6:109-110.
- 8. Singh TG, Sharma R, Kaur A, Dhiman S, Singh R. Evaluation of renoprotective potential of Ficus religiosa in attenuation of diabetic nephropathy in rats. Obes Med. 2020; 19: 100268.
- 9. Al-masri IM, Mohammad MK, Tahaa MO. Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberine. J enzyme inhib med chem. 2009; 24(5):1061–1066.
- 10. Chinmay D, Deshmukh, Jain A. Diabetes Mellitus: A Review. Int. J. Pure App. Biosci. 2015; 3(3): 224-230.
- 11. Nathan DM, Buse JB, Davidson MB. Medical management of hyperglycemia in type 2 diabetes: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32:193–203.
- 12. Pratley RE, Gilbert M. Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor agonists and DPP-4 inhibitiors. Rev of Diabet Stud. 2008; 5:73-94.
- 13. Amori RE, Lau J, Pittas AG. Efficacy and Safety of incretin therapy in type 2 diabetes: Systemic Review and Analysis. JAMA. 2007; 298:194-206.
- 14. Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman DE, Khatami H. Efficacy and safety of the Dipeptidyl Peptidase-4 inhibitor Sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia. 2006; 49:2564-71.
- 15. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE. Effect of the Dipeptidyl Peptidase-4, inhibitor Sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006; 29:2632-37.
- 16. Cherbonnel B, Karasik A, Liu J, Wu M, Menininger G. Efficacy and safety of the Dipeptidyl Peptidase-4 inhibitor Sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006; 29:2638-43.
- 17. Hermansen K, Kipnes M, Luo E, Fanurik D, Khataami H, Stein P. Efficacy and Safety of the dipeptidyl peptidase-4 inhibitor, Sitagliptin, in patients with type 2 diabetes inadequately controlled on glimepiride alone or on glimepiride and Metformin. Diabetes Obese Metab. 2007; 9:733-45.
- 18. Sharma VK, Singh TG, Insulin resistance and bioenergetic manifestations: Targets and approaches in Alzheimer’s disease. Life Sci. 2020; 118401.